Intrathecal Morphine Following Lumbar Fusion: A Placebo-Controlled Trial

Daniel Yavin¹-², Perry Dhaliwal³-⁷, Tara Whittaker¹, Geoffrey S. Hawboldt⁴, Gordon A. E. Jewett⁵, Steven Casha¹-⁶, Stephan du Plessis¹

¹Division of Neurosurgery, Department of Clinical Neurosciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada, ²Department of Community Health Sciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada, ³Division of Neurosurgery, Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada, ⁴Department of Anesthesia, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada, ⁵Division of Neurology, Department of Clinical Neurosciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada, ⁶The Hotchkiss Brain Institute, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada, ⁷Drs. Dhaliwal and Yavin contributed equally to this article, Calgary, Alberta, Canada

Objectives

To evaluate the safety and efficacy of intrathecal morphine following lumbar fusion.

Method

We randomly assigned 150 patients undergoing instrumented lumbar fusion for degenerative indications to receive a single intrathecal injection of morphine (0.2 mg) or placebo (normal saline) immediately prior to wound closure. An oblique injection technique was used to mitigate the risk of precipitating a cerebrospinal fluid leak. The primary outcome was pain on the visual-analogue scale during the first 24 hours after surgery. Secondary outcomes included respiratory depression, treatment-related side effects, postoperative opioid requirements, and length of hospital stay. An intention-to-treat, repeated-measures analysis was used to estimate outcomes according to treatment.

Results

The baseline characteristics of the two groups were similar. Intrathecal morphine reduced pain both at rest (32% area under the curves [AUCs] difference, P < 0.002) and with movement (22% AUCs difference, P < 0.02) during the initial 24 hours after surgery. The risk of respiratory depression was not increased by intrathecal morphine (hazard ratio, 0.86; 95% confidence interval, 0.44 to 1.68; P = 0.66). Although postoperative opioid requirements were reduced with intrathecal morphine (P<0.03), lengths of hospital stay were similar (P = 0.32). Other than a trend towards increased intermittent catheterization among patients assigned to intrathecal morphine (P = 0.09), treatment-related side effects did not significantly differ between the two groups. The early benefits of intrathecal morphine on postoperative pain were no longer apparent from 48 hours onwards.

Conclusions

A single intrathecal injection of 0.2 mg of morphine safely reduces postoperative pain following lumbar fusion. (Funded by the Alberta Spine Foundation; ClinicalTrials.gov number, NCT01053039.)

NOTE: Daniel Yavin was the recipient of the award for the 2017 Best Resident’s Paper at the 2017 Annual Scientific Conference of the Canadian Spine Society for this abstract presentation.